Gilde Healthcare has raised €250M for its 4th fund in an oversubscribed round. The money will go to late-stage MedTech, digital health and therapeutics, which can join a portfolio with some of the European celebrity-Biotechs.
Gilde Healthcare is based in Utrecht (Netherlands) and Cambridge (Massachussets), investing in healthcare companies on both sides of the Atlantic.
This VC has now raised €250M for its 4th fund – Gilde Healthcare IV. The round was backed by a mix of international investors, which included well-known Dutch company Philips (technology giant also with MedTech products) and Johnson & Johnson Innovation (US).
For the IV Fund, single investments in each biotech will be between €15M and €25M. The current portfolio includes companies like Agendia (which developed a diagnostic test for breast cancer), Acacia (developing anti-nausea medication) and Symphogen (one of the top biotechs in Copenhagen).
Gilde’s strategy to investing focuses on later stages of Biotech, MedTech and Digital Health companies (such as Series C rounds). Some of the big names in Gilde’s exits wall of fame are Ablynx, Evotec, UniQure and Galapagos.
Even with its late-stage strategy (less risk, but also less potential for growth in portfolio companies), a quarter of a billion euros is still very impressive. It beats other 2016 rounds for investment funds, like the €210M launch of Medicxi Ventures in February, the €180M fundraising by Forbion in April and the €204M fundraising by MVM Capital in May.
This is yet another example of how VC financing is strong in biotech. Which biotechs could now become part of Gilde’s portfolio?